The roles and regulatory mechanisms of ferroptosis (a non-apoptotic form of cell death) in cancer remain unclear. The tumour suppressor BRCA1-associated protein 1 (BAP1) encodes a nuclear deubiquitinating enzyme to reduce histone 2A ubiquitination (H2Aub) on chromatin. Here, integrated transcriptomic, epigenomic and cancer genomic analyses link BAP1 to metabolismrelated biological processes, and identify cystine transporter SLC7A11 as a key BAP1 target gene in human cancers. Functional studies reveal that BAP1 decreases H2Aub occupancy on the SLC7A11 promoter and represses SLC7A11 expression in a deubiquitinating-dependent manner, and that BAP1 inhibits cystine uptake by repressing SLC7A11 expression, leading to elevated lipid peroxidation and ferroptosis. Furthermore, we show that BAP1 inhibits tumour development partly through SLC7A11 and ferroptosis, and that cancer-associated BAP1 mutants lose their abilities to repress SLC7A11 and to promote ferroptosis. Together, our results uncover a previously unappreciated epigenetic mechanism coupling ferroptosis to tumour suppression.
T o survive, cancer cells require an adequate supply of nutrients, such as amino acids, to maintain redox homeostasis and to meet their biosynthetic and bioenergetic needs 1, 2 . Nutrient depletion induces metabolic stress and eventually provokes cell death, including apoptosis and other non-apoptotic forms of regulated cell death 3, 4 . Cancer cells engage strategies of metabolic adaptation, including inactivation of apoptosis pathways, to survive under metabolic stress conditions and to allow tumour progression 5, 6 . It is conceivable that non-apoptotic cell death pathways are also dysregulated in cancer, although the underlying mechanisms remain much less understood.
Ferroptosis is a recently identified metabolic stress-induced non-apoptotic form of regulated cell death that is caused by cystine depletion and overproduction of lipid-based reactive oxygen species (ROS), particularly lipid hydroperoxide, in an iron-dependent manner [7] [8] [9] [10] [11] . Solute carrier family 7 member 11 (SLC7A11, also called xCT), the catalytic subunit of the cystine/glutamate antiporter system x c − , is the major transporter of extracellular cystine [12] [13] [14] . Correspondingly, cystine depletion or drugs that block SLC7A11-mediated cystine uptake, such as erastin, induce ferroptosis 7 . Intracellular cystine is rapidly converted to cysteine, which subsequently serves as the rate-limiting precursor for glutathione synthesis. Glutathione peroxidase 4 (GPX4) utilizes reduced glutathione (GSH) to reduce lipid hydroperoxides to lipid alcohols, to protect cells against membrane lipid peroxidation and inhibit ferroptosis 15, 16 . Ferroptosis is morphologically, genetically and biochemically distinct from other forms of regulated cell death, such as apoptosis and necroptosis 7 . It is well established that cell death, most notably apoptosis, plays important roles in tumour suppression 17, 18 .
However, the roles and regulatory mechanisms of ferroptosis in tumour biology remain largely unexplored.
BRCA1-associated protein 1 (BAP1) encodes a nuclear deubiquitinating (DUB) enzyme that interacts with several transcriptional factors and chromatin-modifying enzymes, such as FOXK1/2, ASXL1/2, OGT, HCFC1 and KDM1B, and plays an important role in the epigenetic regulation of gene transcription [19] [20] [21] [22] [23] [24] [25] . BAP1 and its associated proteins form the polycomb repressive deubiquitinase (PR-DUB) complex, which mainly functions to remove monoubiquitin from ubiquitinated histone 2A at lysine 119 (H2Aub) 26 . It has been shown that this type of histone modification regulates gene transcription through epigenetic mechanisms [27] [28] [29] . BAP1 is a tumour suppressor gene with frequent inactivating mutations and deletions in a variety of sporadic human cancers, including uveal melanoma (UVM), renal cell carcinoma, mesothelioma and cholangiocarcinoma 19, [30] [31] [32] [33] . However, the mechanisms by which BAP1 exerts its tumour suppression function, particularly the extent to which BAP1 regulation of H2Aub levels on chromatin and corresponding transcriptional targets plays a role in its tumour suppression function, remain unclear. In this study, we conduct integrative analyses to achieve a comprehensive identification of BAP1-regulated target genes and relevant biological processes in cancer cells, and identify a BAP1-mediated epigenetic mechanism that links ferroptosis to tumour suppression.
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NATuRe CeLL BioLogy transcriptional alterations in the genome. To this end, we established UMRC6 cells (a BAP1-deficient renal cancer cell line) with stable expression of an empty vector (EV), BAP1 wild type (WT) and a BAP1 C91A DUB-inactive mutant 34 . We confirmed that re-expression of BAP1 WT, but not its C91A mutant, in UMRC6 cells decreased global H2Aub levels (Fig. 1a ). We then performed H2Aub chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) analyses in these cells. Our ChIP-seq analyses revealed that re-expression of BAP1 WT, but not its C91A mutant, resulted in significant reduction of genome-wide H2Aub occupancies in UMRC6 cells (Fig. 1b,c) . Distribution analysis showed that more than half of H2Aub bindings in EV/WT/C91A cells were detected at promoter or gene body regions ( Supplementary Fig. 1a ). BAP1 WT, but not BAP1 C91A, cells showed decreases of H2Aub occupancies at promoter, gene body and intergenic regions ( Fig. 1d and Supplemenary Fig. 1b ). Overall, we identified more than 5,000 genes with reduced H2Aub occupancies in BAP1 WT cells compared with EV cells (Fig. 1e ; false discovery rate (FDR) < 0.001).
Parallel RNA sequencing (RNA-seq) analysis identified around 1,700 differentially expressed genes (983 upregulated genes and 717 downregulated genes) on BAP1 re-expression in UMRC6 cells ( Supplementary Fig. 1c ; fold change > 1.5, FDR < 0.05). Integration of both H2Aub ChIP-seq and RNA-seq data sets identified 354 BAP1-upregulated genes and 187 BAP1-downregulated genes with BAP1-dependent H2Aub reduction in both gene sets ( Fig. 1f and Supplementary Table 1 ). The current model proposes that H2Aub is associated with transcriptional repression 28 , which would predict that BAP1-dependent H2Aub reduction correlates with BAP1mediated transcriptional activation. To test this hypothesis, we conducted gene set enrichment analysis (GSEA) on the genes with different fold changes in BAP1-dependent H2Aub reduction (5, 837 genes whose H2Aub levels were reduced by BAP1 > 1.6-fold, 1,494 genes > 2-fold, and 101 genes > 2.5-fold). GSEA revealed, in all three analyses, that genes with BAP1-dependent H2Aub reduction were enriched with BAP1-upregulated genes; indeed, the more stringent the cutoff we used, the more significant the correlation (see Fig. 1g for 101 genes, normalized enrichment score = 1.61, FDR = 0; see Supplementary Fig. 1d for 1,494 genes, normalized enrichment score = 1.52, FDR = 0; see Supplementary Fig. 1e for 5,837 genes, normalized enrichment score = 1.22, FDR = 0). Thus, our analysis was consistent with the prevailing model that H2Aub correlates with transcriptional repression 28 . It is also worth noting that the fold changes in H2Aub binding on promoters of the genes that were differentially regulated by BAP1 were more pronounced than those in the total set of 5,837 genes ( Fig. 1d ,h,i and Supplementary  Fig. 1b ,f,g; with the following median log 2 -fold change of H2Aub on BAP1 re-expression: − 0.44 for all 5,837 genes versus − 1.03 for BAP1-downregulated genes versus − 0.96 for BAP1-upregulated genes). Thus, BAP1-dependent H2Aub de-ubiquitination correlates with BAP1-mediated transcriptional alteration. Heatmap analysis of the H2Aub profile around transcriptional start sites (TSSs) revealed that the genes that were upregulated or downregulated by BAP1 displayed reduced H2Aub signals centred on TSSs on re-expression of BAP1 WT, but not C91A ( Fig. 1j ).
Gene ontology (GO) analysis of 354 BAP1-upregulated and 187 BAP1-downregulated genes revealed that, while BAP1-upregulated genes were enriched in diverse cellular processes (Supplementary Fig. 1h and Supplementary Table 1 ), the genes that were downregulated by BAP1 showed striking enrichment in metabolism-related biological processes, among which 'response to oxidative stress' was the most significantly enriched ( Fig. 1k and Supplementary Table 1 ). Together, our genome-wide analyses suggested that BAP1-mediated de-ubiquitination of H2Aub is associated with both transcriptional activation and repression of gene targets involved in different biological processes (see Discussion), and linked BAP1-repressed genes to metabolism.
Cancer genomic analyses link SLC7A11 to BAP1-mediated tumour suppression in human cancers. Next, we studied the potential relevance of BAP1-regulated genes to BAP1-mediated tumour suppression in human cancers through analysis of The Cancer Genome Atlas (TCGA) data sets. Because we conducted our genome-wide analyses in a renal cancer cell line, we focused on the TCGA Kidney Clear Cell Carcinoma (KIRC) data set 35 in our initial analysis. Specifically, we subjected the list of 541 genes (187 BAP1-downregulated and 354 BAP1-upregulated genes with reduced H2Aub occupancies; Fig. 1f ) to a series of computational analyses, including (1) expression correlation with BAP1 in KIRC, (2) comparison of expression in KIRC and normal kidneys and (3) patient survival prediction in KIRC ( Fig. 2a ). We aimed to identify BAP1-downregulated target genes (1) whose expression is inversely correlated with that of BAP1 in KIRC, (2) that are upregulated in KIRC compared with normal kidneys, and (3) whose upregulation correlates with shorter patient survival, and vice versa. Such analyses identified 20 BAP1-downregulated and 26 BAP1-upregulated genes that satisfied all three criteria, among which SLC7A11 was the only downregulated gene, whereas Shroom3 and PARD3B were the upregulated genes that showed statistical significance in all three analyses ( Supplementary Table 2 ). Notably, SLC7A11 was among the top genes identified in our RNA-seq and H2Aub ChIP-seq analyses ( Fig. 1j and Supplementary Fig. 1c ), and also among the genes involved in 'response to oxidative stress' , the most significantly enriched biological process of BAP1-downregulated genes from the GO analysis (Supplementary Table 1 ). We therefore focused on SLC7A11 in the follow-up studies.
As shown in Fig. 2b-d , our analyses revealed that SLC7A11 expression inversely correlated with BAP1 expression in KIRC, that SLC7A11 exhibited higher expression in KIRC than in normal kidneys, and that higher expression of SLC7A11 predicted shorter survival in KIRC patients. We then extended the same analyses of SLC7A11 to other TCGA data sets. Such analyses revealed that BAP1 expression inversely correlated with SLC7A11 expression not only in KIRC, but also in several other human cancers, including kidney papillary cell carcinoma (KIRP), UVM, pheochromocytoma and paraganglioma (PCPG) and breast invasive carcinoma (BRCA) [36] [37] [38] [39] (Fig. 2e ). Consistent with this, we observed an inverse correlation between BAP1 and SLC7A11 levels across a panel of cancer cell lines ( Fig. 2f ). Further comparison of the expression levels of SLC7A11 in KIRP, PCPG, BRCA and corresponding normal tissues showed that SLC7A11 is upregulated in these cancers ( Fig. 2g ). (Note that there was no normal tissue control for UVM in the TCGA or GTEx databases, so we were unable to conduct the analysis for UVM.) Correspondingly, BAP1 is mutated/ deleted (in UVM, KIRC and KIRP) or downregulated (in PCPG and BRCA) in these tumour types with SLC7A11 high expression ( Fig. 2h,i ). Finally, we showed that, in KIRP and UVM, patients with high SLC7A11 expression had shorter overall survival than did patients with low SLC7A11 expression, whereas UVM patients with lower BAP1 expression had significantly shorter overall survival ( Fig. 2j-l) . In KIRP and UVM, the combination of high SLC7A11 and low BAP1 expression predicted even worse clinical outcomes than either parameter alone ( Fig. 2m ,n). Together, our analyses identified SLC7A11 as one of the most relevant target genes in BAP1-mediated tumour suppression in human cancers, and revealed that BAP1 and SLC7A11 expression levels show an inverse correlation and predict clinical outcomes in human cancers.
BAP1 suppresses SLC7A11 expression and reduces H2Aub
occupancy on the SLC7A11 promoter. The aforementioned computational analyses prompted detailed mechanistic studies on how BAP1 regulates SLC7A11. UMRC6 cells, the BAP1-deficient cell line used in our RNA-seq and H2Aub ChIP-seq analyses, exhibited high SLC7A11 expression ( Fig. 2f ). We confirmed that 
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NATuRe CeLL BioLogy re-expression of BAP1 WT, but not its C91A mutant, in UMRC6 cells decreased SLC7A11 expression ( Fig. 3a-c ), suggesting that BAP1-mediated repression of SLC7A11 expression requires BAP1's DUB activity. Similarly, BAP1 re-expression in NCI-H226 cells, a BAP1-deficient mesothelioma cell line with high SLC7A11 expression ( Fig. 2f ), also repressed SLC7A11 expression ( Supplementary   Fig. 2a,b ). Conversely, BAP1 deficiency by CRISPR technology increased SLC7A11 expression in several BAP1-proficient renal cancer cells with low SLC7A11 levels, including 786-O, Caki1 and ACHN cells ( Fig. 3d,e and Supplementary 2c-f). Importantly, restoration of BAP1 WT, but not its C91A mutant, in BAP1 CRISPR knockout (KO) (sgBAP1) 786-O cells decreased SLC7A11 expression 
139,100,000 139,150,000 139,200,000 SLC7A11 Error bars are mean ± s.d., n = 3 independent repeats (a). The experiment was repeated four times, independently, with similar results (b). c, BAP1 (red) and SLC7A11 (green) expression and localization in indicated cells were analysed by immunofluorescence. Cell nuclei were labelled by DAPI (blue) staining. Scale bar, 10 µ m. The experiment was repeated twice independently with similar results. d,e, mRNA and protein levels of indicated genes in indicated 786-O cells were measured by RT-PCR (d) and western blotting (e). Error bars are mean ± s.d., n = 3 independent repeats (d). The experiment was repeated three times, independently, with similar results (e). f,g, mRNA and protein levels of indicated genes in indicated 786-O cells were measured by RT-PCR (f) and western blotting (g). Error bars are mean ± s.d., n = 3 independent repeats (f). The experiment was repeated twice, independently, with similar results (g). h, H2Aub ChIP-seq occupancy profiles at the SLC7A11 loci in indicated UMRC6 cells. i, ChIP-qPCR confirming the lower H2Aub binding on the SLC7A11 promoter and selected exon regions in BAP1 WT cells than in EV or BAP1 C91A cells. Error bars are mean ± s.d., n = 3 independent repeats. j, ChIP-qPCR showing the increased H2Aub binding on the SLC7A11 promoter with BAP1 deficiency in 786-O cells. Error bars are mean ± s.d., n = 3 independent repeats. k, ChIP-qPCR analysis of RNA polymerase II (Pol II), S5-CTD and S2-CTD binding on the SLC7A11 promoter and selected exon regions. Error bars are mean ± s.d., n = 3 independent repeats. l, Lists of BAP1 binding proteins identified by mass spectrometry. m, Interactions between indicated proteins and BAP1 were verified by western blotting in the indicated cells. The experiment was repeated twice, independently, with similar results. n, Bar graph showing the binding of PR-DUB proteins on the SLC7A11 promoter by ChIP-qPCR. Error bars are mean ± s.d., n = 3 independent repeats. All P values were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 7 .
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to a level similar to that in 786-O control cells ( Fig. 3f,g) . In addition, Bap1 deletion in mouse embryonic fibroblasts (MEFs) 34 increased SLC7A11 expression ( Supplementary Fig. 2g ). A luciferase assay with the SLC7A11 promoter showed that overexpression of BAP1 WT, but not its C91A mutant, decreased luciferase activity, whereas BAP1 knockdown increased it, indicating that BAP1 regulates SLC7A11 transcription ( Supplementary Fig. 2h ,i). Previous studies showed that the tumour suppressor p53 represses SLC7A11 expression 40, 41 . Re-expression of BAP1 in UMRC6 cells did not significantly affect p53 levels ( Supplementary  Fig. 2j ). We then studied whether p53 plays a role in BAP1 regulation of SLC7A11 expression. Consistent with previous findings in other cell lines 40 , we confirmed that p53 deletion via CRISPR technology increased SLC7A11 levels in UMRC6 cells ( Supplementary Fig. 2k ). However, restoring BAP1 in p53-deficient cells still inhibited SLC7A11 expression ( Supplementary Fig. 2l-n) , and the fold change in SLC7A11 expression by BAP1 restoration in p53-deficient cells was similar to that in p53-proficient cells ( Supplementary Fig. 2o ), suggesting that BAP1 represses SLC7A11 expression independent of p53.
Analysis of our H2Aub ChIP-seq data revealed that restoration of BAP1 WT, but not BAP1 C91A, markedly decreased H2Aub occupancy at both the promoter and gene body of SLC7A11 ( Fig. 3h ), which was further confirmed by an H2Aub ChIP assay on the SLC7A11 promoter and representative exons ( Fig. 3i and Supplementary Fig. 2p ). Conversely, we showed that BAP1 deletion increased global H2Aub levels in 786-O, Caki1 and ACHN cells ( Fig. 3e and Supplementary Fig. 2c ,e) and promoted H2Aub binding on the SLC7A11 promoter in 786-O cells (Fig. 3j ). It has been shown that H2Aub regulates both transcription initiation and elongation 42 , which are associated with different phosphorylation patterns of the heptad repeats of the C-terminal domain (CTD) of the largest subunit of RNA polymerase II: transcription initiation is associated with CTD serine 5 phosphorylation (S5-CTD), while transcription elongation is associated with CTD serine 2 phosphorylation (S2-CTD) 43 . We found that BAP1 decreased S5-CTD binding on the SLC7A11 promoter and S2-CTD binding on exons of SLC7A11 in a DUB-dependent manner ( Fig. 3k and Supplementary  Fig. 2q ) (but BAP1 did not decrease the total protein levels of RNA polymerase II, S5-CTD or S2-CTD; Supplementary Fig. 2r ). Our data thus suggest that BAP1-mediated H2Aub de-ubiquitination on SLC7A11 correlates with inhibition of both transcription initiation and elongation.
BAP1 interacts with several transcriptional factors and chromatin-modifying factors, forming the PR-DUB complex 19, 20 . Indeed, mass spectrometry analysis identified all known protein components of the PR-DUB complex as top-ranking BAP1-interacting proteins (Fig. 3l ), and some of the interactions were further confirmed by co-immunoprecipitation analysis (Fig. 3m ). It should be noted that BAP1 did not appear to affect the protein levels of other PR-DUB components ( Supplementary Fig. 3a ). It has been suggested that BAP1 is recruited to chromatin through the transcriptional factors and chromatin-modifying factors in the PR-DUB complex, such as FOXK1/2 and ASXL1/2 19 . A previous study generated ChIP-seq data sets for several components in the PR-DUB complex, including FOXK1, ASXL1 and O-GlcNAC (a readout for OGT) 44 . We therefore integrated these ChIP-seq data sets with our H2Aub data sets. These analyses identified around 3,000 genes that are co-occupied by FOXK1, ASXL1 and O-GlcNAC; among these, 1,140 genes also exhibit BAP1-dependent decrease in H2Aub occupancy ( Supplementary Fig. 3b ). Notably, analysis of these ChIPseq data sets revealed striking bindings of ASXL1, FOXK1 and O-GlcNAC on the SLC7A11 promoter ( Supplementary Fig. 3c ). The bindings of PR-DUB complex proteins on the SLC7A11 promoter were further validated by ChIP assay (Fig. 3n ). Knockdown of some PR-DUB components also affected SLC7A11 expression ( Supplementary Fig. 3d-m ). Together, our data suggested a model that the BAP1-containing PR-DUB complex binds on the SLC7A11 promoter, where BAP1 removes ubiquitin from H2Aub, and BAP1dependent H2Aub reduction on SLC7A11 is associated with BAP1mediated SLC7A11 repression.
BAP1 suppresses SLC7A11-mediated cystine uptake and promotes ferroptosis. SLC7A11 mediates the uptake of extracellular cystine, a major precursor for glutathione biosynthesis 12, 14 . Glutathione is then utilized by GPX4 to detoxify lipid hydroperoxide and to protect cells from ferroptosis 15 . Consistently, we observed that re-expression of BAP1 WT, but not its C91A mutant, in UMRC6 cells inhibited cystine uptake (Fig. 4a ), decreased GSH levels ( Fig. 4b ) and increased erastin-induced lipid peroxidation (Fig. 4c ). Erastin treatment potently induced SLC7A11 expression without affecting BAP1 expression ( Supplementary Fig. 4a,b ). In addition, erastin potently induced SLC7A11 expression in BAP1-deficient cells ( Supplementary Fig. 4c,d ), suggesting that BAP1 represses the basal expression of SLC7A11 and that erastin induces SLC7A11 expression, probably through BAP1-independent mechanisms.
We next studied the potential role of BAP1 in ferroptosis. We showed that treatment with tert-butyl hydroperoxide (TBH), a ROS inducer 40 , resulted in substantially more cell death in BAP1 WT cells than in EV or BAP1 C91A cells ( Fig. 4d and Supplementary Fig. 4e ). Importantly, TBH-induced cell death could be largely suppressed by the ferroptosis inhibitor ferrostatin or the iron chelator deferoxamine (DFO), but not by the apoptosis inhibitor Z-VAD-fmk or the necroptosis inhibitor necrostatin-1s ( Fig. 4d ). Similarly, BAP1 WT, but not its C91A mutant, significantly potentiated erastin-induced cell death (Fig. 4e,f and Supplementary Fig. 4f ), and erastin-induced cell death could be fully suppressed by ferrostatin or DFO, but not by Z-VAD-fmk or necrostatin-1s ( Fig. 4g and Supplementary Fig. 4f ). Erastin treatment did not induce poly (ADP-ribose) polymerase (PARP) cleavage ( Fig. 4g ), confirming that erastin did not induce apoptosis. Cystine depletion also induces ferroptosis 45 . We observed that expression of BAP1 WT, but not the BAP1 C91A mutant, sensitized UMRC6 cells to cystine-depletion-induced cell death, which could be fully suppressed by ferrostatin ( Fig. 4h,i ). Re-expression of BAP1 in NCI-H226 cells, another BAP1-deficient cell line, similarly potentiated TBH-or erastin-induced ferroptosis ( Supplementary  Fig. 4h Supplementary Fig. 4l ,m) rendered cells more resistant to erastin-or cystine-depletion-induced ferroptosis. Importantly, re-expression of BAP1 WT, but not its C91A mutant, in BAP1 KO 786-O cells restored ferroptosis sensitivity ( Fig. 4o ). Finally, analysis of ferroptosis sensitivity in the panel of cell lines (Fig. 2f ) revealed that all three BAP1-low/SLC7A11-high cell lines were resistant to erastin-induced ferroptosis, whereas five of seven BAP1-high/SLC7A11-low cell lines were sensitive to erastininduced ferroptosis ( Supplementary Fig. 4n ). Taken together, our results convincingly showed that BAP1 promotes ferroptosis in a DUB-dependent manner.
BAP1 regulates ferroptosis through SLC7A11. We next sought to determine whether BAP1 promotes ferroptosis by mediating repression of SLC7A11 expression. Restoration of SLC7A11 in UMRC6 BAP1 cells normalized cystine uptake, lipid peroxidation accumulation, and erastin-, ROS-or cystine-depletion-induced ferroptosis to levels similar to those observed in UMRC6 EV cells ( Fig. 5a-g) . We also restored SLC7A11 expression in NCI-H226 BAP1 cells and made similar observations ( Supplementary Fig. 5a-e ). Conversely, SLC7A11 knockdown in UMRC6 and NCI-H226 cells, two BAP1deficient cancer cells that exhibited high SLC7A11 expression and were resistant to ferroptosis ( Fig. 2f and Supplementary Fig.  4n ), sensitized the cells to erastin-or cystine-depletion-induced Articles NATuRe CeLL BioLogy ferroptosis (Fig. 5h-k and Supplementary Fig. 5f-i) . Finally, SLC7A11 knockdown in sgBAP1 786-O cells (which exhibited increased SLC7A11 expression) also re-sensitized the cells to ferroptosis ( Fig. 5l-n) . Collectively, our data strongly suggest that BAP1 promotes ferroptosis mainly through BAP1-mediated repression of SLC7A11 expression. Supplementary Fig. 7 .
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NATuRe CeLL BioLogy BAP1 inhibits tumour development partly through SLC7A11 and ferroptosis. We also studied the role of BAP1 regulation of SLC7A11 in BAP1-mediated tumour suppression. BAP1 re-expression in UMRC6 cells markedly inhibited anchorage-independent growth in a DUB-dependent manner (Fig. 6a ). SLC7A11 knockdown in UMRC6 cells significantly inhibited anchorage-independent growth (Fig. 6b ), and importantly, restoration of SLC7A11 in UMRC6 BAP1 WT cells partially restored anchorage-independent growth compared with UMRC6 EV cells (Fig. 6c ). It should be noted that BAP1 re-expression or SLC7A11 knockdown affected cell proliferation marginally (Fig. 6d,e ). Consistently, we showed that BAP1 re-expression in a BAP1-deficient background markedly inhibited xenograft tumour development and that restoration of SLC7A11 in BAP1-expressing cells partially restored tumour development ( Fig. 6f ), while SLC7A11 knockdown in a BAP1-deficient background inhibited xenograft tumour development (Fig. 6g,h) .
In addition, BAP1 deletion in a BAP1-proficient background markedly increased xenograft tumour development, and restoration of BAP1 WT, but not BAP1 C91A mutant, repressed tumour development ( Fig. 6i ). Taken together, our data suggest that BAP1 suppresses tumour development in a DUB-dependent manner and at least partly through SLC7A11. Next, we studied the potential relevance of ferroptosis in BAP1mediated tumour suppression. Electron microscopy (EM) analysis revealed that many tumour cells from xenograft tumours with BAP1 re-expression contained shrunken mitochondria with increased membrane density, a morphologic feature of ferroptosis 7 . In contrast, we never observed such cells in EV tumour samples (Fig.  6j ). Because ferroptosis is characterized by overproduction of lipid peroxidation, we conducted 4-hydroxy-2-noneal (4HNE) immunohistochemistry (IHC) analysis to characterize lipid peroxidation levels 46 in EV and BAP1-re-expressing tumour samples. These studies revealed increased 4HNE staining in tumour cells, but not the surrounding lymphocytes, from BAP1-re-expressing tumours compared with cells from EV tumours (Fig. 6k,l) . Finally, we showed that treatment with the ferroptosis inhibitor liproxstatin-1 16 , while it did not affect EV tumour development, partially restored tumour development in BAP1-re-expressing tumours (Fig. 6m ). Together, our data suggest that BAP1 promotes ferroptosis in vivo and that ferroptosis is at least partly responsible for BAP1's tumour suppression function in vivo.
Cancer-associated BAP1 mutations are defective in regulating SLC7A11 and ferroptosis. Many BAP1 mutations have been identified in human cancers. A survey of cancer genomics data sets from the cBioPortal for Cancer Genomics 47,48 as of September 2017 identified about 500 somatic mutations in BAP1, including 211 nonsense (truncating) mutations and 283 missense mutations ( Supplementary Fig. 6a ). Importantly, KIRC patients with BAP1 mutations had poor clinical outcomes ( Supplementary Fig. 6b ).
To study the effect of cancer-associated BAP1 missense mutations on ferroptosis and tumour suppression, we first utilized the Mutation Assessor from cBioPortal (http://mutationassessor.org/r2/) to predict and rank the functional impact scores of all missense mutations identified in BAP1. These analyses identified eight BAP1 mutations with the highest functional impact scores ( Supplementary  Table 3 ). Notably, all eight mutations are located within the UCH domain, which mediates the DUB activity of BAP1 (Fig. 7a) . In fact, one mutation, C91G, is equivalent to C91A, which was used as the DUB-inactive mutant in our study. Thus, the mutation analyses strongly suggested an important role for BAP1 DUB function in human cancer. We then expressed each of these cancer-associated BAP1 mutants, as well as BAP1 WT and the C91A mutant, in UMRC6 cells. Remarkably, all BAP1 mutants, except G109V, behaved as loss-of-function mutants and were incapable of repressing SLC7A11 expression ( Fig. 7b,c) or promoting erastin-or cys-tine-depletion-induced ferroptosis (Fig. 7d,e and Supplementary  Fig. 6c ). We further showed that, while these mutants only affected cell proliferation moderately at most ( Supplementary Fig. 6d,e ), all mutants except G109V at least partially lost their abilities to inhibit anchorage-independent growth (Fig. 7f) .
These BAP1 mutants did not significantly affect BAP1's interaction with other components of the PR-DUB complex ( Supplementary Fig. 6f) . Notably, we observed that all BAP1 mutants except G109V were incapable of downregulating H2Aub (Fig. 7b ), suggesting that these BAP1 mutants are at least partially DUB-inactive toward H2Aub. Overall, we observed strong correlations of these cancer-associated BAP1 mutants in terms of their effects on H2Aub levels, SLC7A11 expression, ferroptosis sensitivity and anchorage-independent growth. Collectively, our results provided direct evidence to link BAP1's functions in regulating H2Aub, SLC7A11 expression and ferroptosis to its tumour suppression function in human cancer, and further suggested that BAP1's DUB function of removing H2Aub is involved in its regulation of SLC7A11 expression, ferroptosis and tumour suppression.
Discussion
Tumour cells require an appropriate supply of amino acids, including cystine, to survive, grow and proliferate. Cystine plays important roles in maintaining redox balance and promoting cell survival in tumour cells, and an insufficient cystine supply induces metabolic stress and provokes ferroptotic cell death in tumour cells 7 . Tumour cells engage different strategies to ensure an adequate supply of cystine from the tumour microenvironment. In some tumour cells with low expression of cystine transporter SLC7A11, such as chronic lymphocytic leukaemia cells, stromal cells surrounding the tumour take up cystine, convert cystine to cysteine, and release cysteine into the tumour microenvironment; cysteine reuptake into tumour cells then promotes survival 49 . In contrast, other types of tumour cell upregulate the expression of SLC7A11 and maintain high cystine uptake, although the underlying mechanisms by which tumour cells maintain high SLC7A11 expression remain incompletely understood. Our study revealed an important epigenetic mechanism linking SLC7A11 regulation of ferroptosis to tumour biology. Specifically, our study suggests a model in which the tumour suppressor BAP1 normally functions to repress the expression of SLC7A11 at least partly by deubiquitinating H2Aub on SLC7A11, thereby inhibiting cystine uptake into cells and rendering them more sensitive to ferroptosis. BAP1 inactivation by either mutation or expression downregulation de-represses SLC7A11 expression in tumour cells, resulting in increased cystine uptake and GSH synthesis, enhanced resistance to ferroptotic cell death, and promotion of tumour development. Notably, our integrated transcriptomic/epigenomic/cancer genomic analyses identified SLC7A11 as a BAP1 target with the most relevance to BAP1-mediated tumour suppression in human cancers, suggesting that the model described above is likely to be an important mechanism mediating BAP1's tumour suppression function, although we do not rule out the possibility that other BAP1 targets, either transcriptional or non-transcriptional targets 50 , may also play roles in BAP1-mediated tumour suppression.
Our study suggested that BAP1 represses SLC7A11 expression through BAP1-mediated H2Aub deubiquitination on SLC7A11. Other studies in mammalian cells have also shown that BAP1 represses the expression of some target genes with BAP1-dependent deubiquitination of H2Aub on the corresponding gene promoters 21, 51 . However, the underlying mechanisms by which BAP1mediated H2Aub deubiquitination represses target genes remain poorly understood, given that H2Aub generally correlates with gene repression 29 . One model proposes that both H2A ubiquitination and deubiquitination need to occur in a dynamically regulated manner to maintain the repression of some target genes 52 . Similarly, it has been proposed that the cycling of H2B ubiquitination and 
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NATuRe CeLL BioLogy deubiquitination is critical for transcriptional activation 53 . In line with this model, in Drosophila, the repression of polycomb target genes requires not only polycomb repressive complex 1 (PRC1)mediated H2A ubiquitination, but also BAP1-mediated H2A deubiquitination, suggesting that an appropriate balance between H2A ubiquitination and deubiquitination, rather than H2A ubiquitination per se, is important for the maintenance of polycomb target gene repression 26 . Thus, it is possible that BAP1, by removing ubiquitin from H2Aub on some target genes, such as SLC7A11, facilitates the dynamic cycling of H2Aub, resulting in transcriptional repression of target genes. It will be interesting to test this hypothesis in future studies.
In cell line studies, ferroptosis can be specifically induced by cystine depletion or treatment with drugs such as erastin. It can be characterized by EM analysis and cell death inhibitor rescue experiments (that is, ferroptotic cell death can be prevented by ferroptosis inhibitors but not by inhibitors of other forms of cell death). Currently, our ability to study the clinical relevance of ferroptosis in cancer biology is hindered by a lack of established assays for characterizing ferroptosis in tissue and tumour samples equivalent to cleaved caspase-3 IHC staining for apoptosis. To our knowledge ferroptosis has not previously been identified in tumour samples in vivo. In our study, we conducted EM analysis, the gold standard assay for characterizing cell death, on tumour samples and provided definitive evidence of ferroptosis in tumours with BAP1 re-expression. Our work thus motivates further studies to develop assays that can be routinely used for characterizing ferroptosis in tissue and tumour samples.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0178-0. Supplementary Fig. 7 .
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Methods Cell culture studies. Cell line sources are detailed in the Reporting Summary. All cell lines were free of mycoplasma contamination (tested by the vendor). Bap1 WT and KO MEFs were described in our previous publication 34 . For cystine deprivation experiments, cells were cultured in DMEM with different concentrations of cystine + 10% (vol/vol) dialysed FBS. The use of dialysed FBS is described in our previous publication 54 . To generate stable cell lines overexpressing Flag-BAP1 or mutant BAP1, HEK293T cells were transfected with either pLVX-Flag-BAP1 or mutant BAP1 constructs, together with psPAX.2 and pMD2.G third-generation lentiviral packaging systems using Lipofectamine 3000 reagent (ThermoFisher Scientific), according to the manufacturer's instructions. After 48 h, lentivirus particles in the medium were collected and filtered, then the target cell lines were infected. At 24 h post infection, an appropriate selection antibiotic was added to obtain stable cell lines with successful transduction. To generate CRISPR KO cells, the sgRNAs were cloned into the CRISPR-V2 vector (Addgene, #52961), and lentiviral infection was conducted as described above. After 72 h, single antibiotic selection-positive cells were sorted and plated into 96-well plates. Surviving KO clones were screened by immunoblotting with corresponding antibodies. To generate shRNA-knockdown cell lines, lentiviral transduction with shRNA vectors was conducted as described above. At 72 h later, following antibiotic selection, expression levels of target genes were determined by immunoblotting with corresponding antibodies.
Constructs and reagents. SLC7A11 shRNAs and SLC7A11 cDNA-containing expression vectors are described in our previous publication 55 . Human BAP1 cDNA was cloned into the lentivirus vector pLVX-Puro with N-terminal FLAG tag. A series of mutant pLVX-Flag-BAP1 constructs were generated by PCR mutagenesis using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) for amino acid substitutions according to the manufacturer's instructions. All constructs were confirmed by DNA sequencing. The sequences of primers used in PCR mutagenesis, gRNAs and shRNAs used in this study are listed in Supplementary Table 4 . Erastin, ferrostatin-1 and TBH were obtained from Sigma (E7781, SML0583 and 458139). Z-VAD-fmk was obtained from R&D Systems (FMK001). Necrostatin-1s was obtained from BioVision (2263). Staurosporine was obtained from LC Laboratories (S-9300). All drugs were dissolved according to the manufacturers' instructions.
Cell death, viability and proliferation assays. To measure cell death, cells were seeded in a 12-well plate 1 day before treatment. After treatment with appropriate drugs, cells were trypsinized and collected in a 1.5 ml tube, washed once with PBS, and stained with 2 μ g ml −1 PI (Roche) in PBS. Dead cells (PI-positive cells) were analysed using a BD Accuri C6 flow cytometer (BD Biosciences) 56, 57 . To measure cell viability, 5,000 cells per well were seeded in a 96-well plate 1 day before treatment. Following treatment with the appropriate drugs where indicated, each well was replaced with fresh medium containing Cell Counting Kit-8 (CCK8) reagent (Sigma). After incubation for 1 h at 37 °C, the plate was analysed using a FLUOstar Omega microplate reader (BMG Labtech), and absorbance of the wells was measured at 540 nm. To measure cell proliferation, 1,500 cells per well were seeded in a 96-well plate. At 24 h after seeding, cell viability was measured using CCK8 reagent as described above. This was considered day 0. Later, cell viability was analysed every 24 h, and absorbance was normalized to that measured on day 0. Cell growth was indicated by the fold change from day 0 to as long as day 4, and was graphed 58, 59 .
Lipid peroxidation assay. Lipid peroxidation levels were measured as previously described 15 . Briefly, cells were incubated in a 60 mm dish containing 5 μ M BODIPY 581/591 C11 dye (Invitrogen, D3861). After incubation for 30 min at 37 °C, cells were washed with PBS and trypsinized, then stained with PI (propidium iodide) in PBS for 5 min. Cells were then subjected to flow cytometry analysis using an Accuri C6 flow cytometer. The FL1 channel signal in live cells was plotted as shown in the figures.
Cystine uptake assay. Assessment of cystine uptake was conducted using modifications of a previously described protocol 49 . Briefly, cells were seeded in a 12-well plate and incubated overnight. To measure cystine uptake, the medium was replaced with fresh DMEM (which contains 200 µ M cystine) containing [ 14 C] cystine (PerkinElmer) (0.04 μ Ci), and cells were incubated for the indicated time periods. Uptake was terminated by rapidly rinsing cells twice with cold PBS, and lysed in 0.1 mM NaOH. Radioactivity (DPM) was measured using Tri-Carb Liquid Scintillation Analyzer (PerKinElmer, Model 4810TR) in the presence of quench curve. All experiments were carried out in triplicate.
GSH assay. GSH levels were detected using a GSH-Glo Glutathione Assay (Promega) following the manufacturer's instructions. Briefly, 6,000 cells per well were seeded in a 96-well plate 1 day before analysis. The culture medium from the wells was carefully removed, and 100 µ l of prepared 1 × GSH-Glo Reagent was added, followed by incubation at room temperature for 30 min. Next, 100 µ l of reconstituted Luciferin Detection Reagent was added to each well and mixed briefly on a plate shaker. After 20 min, luminescence was measured using a Gen5
Microplate reader (BIOTEK). A standard curve for GSH concentration was generated, and exact GSH concentrations in different cell lines were calculated based on a GSH standard curve according to the manufacturer's instructions.
Light microscopy and immunofluorescence microscopy. For light microscopy, cells cultured in six-well plates were treated with reagents as indicated. Phase contrast images were obtained using an EVOSfl (Advanced Microscopy Group) microscope equipped with a × 10 phase contrast objective. For trypan blue staining, cells were trypsinized and collected in a 1.5 ml tube. Cell pellets were washed once in PBS and then stained with trypan blue (Corning) for 5 min. A × 20 phase contrast objective was used to acquire photographs of stained dead cells. For immunofluorescence microscopy, cells were seeded on glass coverslips and washed with PBS, then fixed in 3.7% formaldehyde. After fixation, cells were washed with PBS and permeabilized for 10 min in 0.1% TritonX-100/PBS. Blocking buffer (5% BSA in 0.1% Triton/PBS) was added for 1 h, followed by incubation with BAP1 (1:500; Santa Cruz, sc-28383) and SLC7A11 (1:500; Cell Signaling Technology, 12691) antibodies overnight. Cells were washed with PBS three times and incubated with fluorescent secondary antibodies (ThermoFisher Scientific) for 2 h. The nuclei were labelled with 4′ ,6-diamidino-2-phenylindole (DAPI, ThermoFisher Scientific), and fluorescence was monitored using a confocal microscope (Leica).
Real-time PCR and ChIP-qPCR.
Real-time PCR was conducted as previously described 60, 61 . ChIP experiments were performed using a SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology, 9003) according to the manufacturer's instructions. After chromatin digestion and sonication, antibodies against target proteins as well as a control antibody were used for ChIP.
The Luciferase reporter assay. The SLC7A11 promoter was amplified using genomic DNA extracted from UMRC6 cells and cloned into pGL3 luciferase reporter vectors. Primers used to clone around 1 kb of the promoter region of SLC7A11 are listed in Supplementary Table 4 . The luciferase reporter assay was conducted using a Dual-Luciferase Reporter Assay System (Promega, E1910) according to the manufacturer's instructions. Briefly, HEK293T cells were transfected with the appropriate plasmids for 48 h, washed with PBS, and lysed for 15 min at room temperature. Cell lysates were transferred to a 384-well plate for subsequent luciferase activity measurement. Luminescence was measured using a Gen5 microplate reader (BIOTEK).
Immunoprecipitation and western blotting. Immunoprecipitation was conducted as previously described 62, 63 . Protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad) using standard techniques. The primary antibodies and concentrations used for western blotting were BAP1 (1:1,000; Santa Cruz, sc-28383), SLC7A11 (1:5,000; Cell Signaling Technology, 12691), tubulin (1:5,000; Cell Signaling Technology, 2144), H2Aub (1:5,000; Millipore, 05-678), H2A (1:5,000; Millipore, ABE327), vinculin (1:10,000; Sigma, V4505), FOXK1 (1:1,000; Abcam, ab18196), FOXK2 (1:1,000; Bethyl Laboratories, A301-730A), HCFC1 (1:1,000; Bethyl Laboratories, A301-399A), OGT (1:1,000, Cell Signaling Technology, 5368), KDM1B (1:1,000; Abcam, ab193080), ASXL1 (1:1,000; Santa Cruz, sc-293204), p53 (1:1,000; Santa Cruz, sc-126), PARP (1:1,000; Cell Signaling Technology, 9542), β -actin (1:4,000; Abcam, ab8226) and V5 (1:2,000; Sigma, A8012).
Tandem affinity purification of SFB-tagged protein complexes. UMRC6 cells with stable expression of S protein, FLAG and streptavidin-binding peptide tag (SFB)-tagged BAP1 were subjected to tandem affinity purification as previously described 64 . Protein bands were excised and subjected to mass spectrometry analysis at the Taplin Mass Spectrometry Facility, Harvard Medical School. Raw mass spectrometry data were processed and further analysed using the MUSE algorithm, as previously described 64 , to assign priority scores to the identified potential interacting proteins.
Xenograft model. Xenograft model experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center. The study is compliant with all relevant ethical regulations regarding animal research. Female 4-to 6-week-old athymic nude mice (Foxn1nu/Foxn1nu) were purchased from the Experimental Histology and IHC. Xenograft tissue samples were collected and immediately fixed in 10% neutral-buffered formalin (ThermoFisher Scientific) overnight. After being washed once with PBS, samples were transferred into 70% ethanol and submitted to the Research Histology Core Laboratory at MD Anderson Cancer Center for embedding and haematoxylin and eosin staining. For IHC staining, tissue sections were processed according to methods described in our previous publications 65, 66 . The antibody used for IHC was anti-4HNE (1:200, Abcam, ab46545). Images were obtained at × 400 magnification using an Olympus BX43 microscope.
Transmission electron microscopy. Xenograft tissue samples were fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, then washed in 0.1 M sodium cacodylate buffer, treated with 0.1% Millipore-filtered cacodylate-buffered tannic acid, postfixed with 1% buffered osmium, and stained en bloc with 1% Milliporefiltered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60 °C oven for approximately 3 days. Ultrathin sections were cut using a Leica Ultracut microtome, stained with uranyl acetate and lead citrate in a Leica EM stainer, and examined with a JEM 1010 transmission electron microscope (JEOL) at an accelerating voltage of 80 kV. Digital images were obtained using an AMT Imaging System (Advanced Microscopy Techniques Corp) at the High Resolution Electron Microscopy Facility at MD Anderson Cancer Center.
ChIP-seq. ChIP was performed using the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology, 9003) following the manufacturer's instructions. Chromatin (20 μ g) was incubated overnight with 5 μ l H2Aub antibody (Cell Signaling Technology, 8240). Next, 100 ng fly chromatin and 0.5 μ g H2Av antibody (Active Motif, 61686) were added to each tube as spike-in controls. Purified ChIP-DNA was verified on agarose gel to ensure proper fragmentation and then sent to the Sequencing and Microarray Facility at MD Anderson Cancer Center for ChIP-seq.
ChIP-seq analysis. Raw reads (single-end, 50 bp) were aligned to human reference genome hg19 using bowtie (v1.1.0), allowing up to one mismatch. Peak calling was performed using model-based analysis of ChIP-seq (MACS, v1.4.2) 67 with a cutoff of P ≤ 1 × 10 -8 . Clonal reads were automatically removed by MACS. Promoter regions were defined as regions 5 kb upstream to 5 kb downstream of the TSS. The H2Aub occupancies at promoter regions were normalized as reads per kilobase per million reads (RPKMs). Fold changes and significance of H2Aub differences between conditions were determined using an MA-plot-based method with a random sampling model, which was implemented in the R package DEGseq 68 ; P values were adjusted using the Benjamini-Hochberg method. For the average profile and heatmap around the TSS, the data matrix was generated using deepTools 69 , and visualization was performed using R. The enriched binding peaks of FOXK1, AXSL1 and O-GlcNAC in HEK293T cells were collected from the GEO database with accession nos. GSM1250375, GSM1250374 and GSM1250376, respectively. The binding targets of these factors were defined as the genes whose promoter regions (3 kb upstream of TSS to 3 kb downstream of TSS) were occupied by the centre of a binding peak.
Gene expression profiling and survival analysis. RNA sequencing was performed in our previous study 34 . The differentially expressed genes on restoring BAP1 in UMRC6 cells were defined by a cutoff of FDR < 0.05 with at least a 1.5-fold change. The expression data of BAP1 and SLC7A11, patient survival data and BAP1 mutation status in five cancer types (UVM, KIRC, KIRP, PCPG and BRCA) were obtained from TCGA, while the expression data for normal samples were from the GTEx database. All these data were generated using the UCSC Xena Browser (http://xena.ucsc.edu/). Survival analysis was conducted on the basis of BAP1 mutation or singular or combined expression of BAP1 and SLC7A11. For survival analysis with combined expression of BAP1 and SLC7A11, survival was compared between two groups of patients separated by the expression of both BAP1 and SLC7A11 using unsupervised clustering; Group 1 had higher BAP1 and lower SLC7A11 expression, while Group 2 had lower BAP1 and higher SLC7A11 expression. The survival impact of different signatures was analysed in R using the Kaplan-Meier method with a Cox proportional hazards model. Code availability. The software and algorithms for data analyses used in this study are all well established from previous work. All software and custom arguments are included in Methods. There is no unreported algorithm used in this paper. Results in Figs. 1, 2 and Supplementary Fig. 1 and 6b can be repeated using the source data in the Supplementary Tables. The source codes for data processing are available  from the corresponding author upon reasonable request. Statistics and reproducibility. Statistical analysis (two-tailed Student's t-test) was performed using R software for Figs. 1b, 2c,g,i and Supplementary Fig. 1b ,f,g, and using GraphPad Prism (GraphPad Software) for other bar graphs in this manuscript. For box plots, the upper and lower edges of the box indicate the first and third quartiles (25th and 75th percentiles) of the data, and the middle line indicates the median. The whiskers extend for 1.5× the interquartile range (25-75% ranges of data) from the edges of the boxes, respectively. The fold changes and significance of H2Aub differences between conditions were determined using an MA-plot-based method with a random sampling model, which was implemented in the R package DEGseq, and the P value was adjusted using the Benjamini-Hochberg method in Fig. 1e ,f. For GO biological process analysis in Fig. 1k, Supplementary Fig. 1h and Supplementary Table 1 , the P value was determined by Fisher exact test, and then adjusted using the Benjamini-Hochberg method. Statistical analysis (two-tailed Student's t-test) was performed using R software for differential expression analysis in Supplementary Table 2 . For survival analysis of the TCGA data set in Fig. 2d ,j,k-n, Supplementary Fig. 6b and Supplementary Table 2 , the log-rank Mantel-Cox test was carried out using R software. Pearson's correlation (two-sided) was performed to analyse gene correlation in Fig. 2b,e and Supplementary Table 2 . To calculate the P value between groups in Figs. 4a,e,h,m,n, 6d,e-g,i,m and Supplementary Figs. 5g and 6d,e, two-way analysis of variance (ANOVA) analysis was performed. All the P values calculated above are indicated in the corresponding figures. Each experiment was repeated successfully more than two times with similar results, as described in the figure captions. To restore BAP1, lentivirus containing BAP1 WT and C91A coding sequence prepared in multiple independent experiments was introduced to BAP1-deficient cells separately, and similar results were found across all cell lines with successful BAP1 protein expression. To knock out or knock down genes of interest, at least two independent sgRNAs or shRNAs were employed to generate cell lines, and similar results were found in all cell lines. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code Data collection Zen (Zeiss) software was used to collect confocal images; Accuri C6 (BD Bioscience) was used to collect flow cytometry data;
Data analysis
ChIP seq analysis: R package DEGseq, bowtie v1.1.0, MACS v1.4.2. ImageJ were used for confocal images analysis; Graphpad were used for bar graphs output and statistic analysis; FlowJo_V10 was used for flow data analysis. Gene expression data were generated using the UCSC Xena Browser (http://xena.ucsc.edu/). The survival impact of different signatures was analyzed in R using the Kaplan-Meier method with a Cox proportional hazards model. The software and algorithms for data analyses used in this study are all well-established from previous work. All software and custom arguments are included in Methods section. There is no unreported algorithm used in this paper. The source code for data processing are available from the corresponding author on reasonable request.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
